# Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

> **NCT00355407** · NA · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 31 (—)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT00355407
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 31 (—)
- **Last updated:** 2009-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355407, "Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00355407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*